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tence and increased health care costs in older adults with demen-
tia in a managed care setting. Health status assessments
completed at enrollment had the potential to identify enrollees at
higher risk for nonadherent behaviors and poor health related
outcomes.
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OBJECTIVE: To evaluate the effectiveness of risperidone
long-acting injection (RLAI) treatment on personal and social
functioning in patients with schizophrenia enrolled in the
electronic-Schizophrenia Treatment Adherence Registry (e-
STAR) from six countries (Canada, Czech Republic, Denmark,
Netherlands, Slovakia, Sweden) that collected Personal and
Social Performance (PSP) data. METHODS: e-STAR is an inter-
national, long-term, prospective, observational study of patients
with schizophrenia who commence RLAI. Data are collected
retrospectively for one year and prospectively every three months
for two years. Personal and social functioning is measured using
the PSP scale which evaluates four areas, socially useful activities,
personal and social relationships, self-care, and disturbing and
aggressive behaviour. Pooled results presented are based on data
from patients who have completed their six-month follow-up
visit. RESULTS: To date, 1831 are enrolled in e-STAR from
the six countries, 1232 patients who have been followed for at
least 6 months are included in this analysis. Mean age was
38.4  12.5 years, 58.6% were male and mean time since diag-
nosis was 9.6  11.6 years. At 6 months, 95.5% of patients are
still on RLAI. The mean PSP score signiﬁcantly improved from
48.0  17.3 at baseline to 64.2  15.2 at 6 months (p < 0.001).
Improvement in PSP was similar for patients hospitalized at
baseline versus those who were ambulatory patients (PSP score
increased by 17.2 and 16.1, respectively, p < 0.001 for both).
Furthermore, signiﬁcant improvement in PSP was seen as soon as
the ﬁrst assessment after RLAI treatment at three months. CON-
CLUSION: These 6-month interim results indicate that personal
and social functioning as measured by the PSP improved with
risperidone long-acting injection treatment in patients with
schizophrenia.
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OBJECTIVE: To measure adherence and persistence in patients
undergoing antipsychotic treatment and their impact on costs
and health-related quality-of-life (HRQoL). METHODS: A
naturalistic, prospective, multicentre cohort study, named
COMETA, was begun in subjects aged 18–40 years, diagnosed
with schizophrenia or schizophreniform disorder 10 years before
the enrolment. Subjects were enrolled and observed for up to
52 weeks in psychiatric centres throughout Italy. Socio-
demographic, clinical, HRQoL and data on resource use were
collected. RESULTS: Six-hundred-sixty-one patients (mean age
31.1 + 5.6, 65.4% male) with schizophrenia (86.5%) or schizo-
phreniform disorder (13.5%) were enrolled in 86 centres during
2006–2007. Most patients had primary/lower secondary level
education (51.9%), and were single (85.9%). A total of 56.6% of
the subjects received help for their disease from relatives/friends,
37.3% of patients were employed, 10.3% were students. The
PANSS (Positive and Negative Syndrome Scale) mean + SD score
was 86.1 + 27.4. The CGI-S (Clinical Global Impression Sever-
ity) mean + SD score was 4.27 + 1.1, the GAF (Global Assess-
ment of Functioning) mean + SD score was 54.3 + 13.8. Ninety
days prior, patients were treated with olanzapine (32.5%), ris-
peridone (31.5%), haloperidol (18.3%), aripiprazole (14.4%),
quetiapine (12.4%) and clozapine (11.2%). Thirty percent of the
patients took >2 different drugs (up to 5) in that period. Regard-
ing HRQoL, 68.7% of patients reported problems on the
anxiety/depression-domain of the EQ-5D, 52.3% on usual activi-
ties, 37.7% on pain/discomfort, 21.4% on mobility and 16.8%
on self-care. The EQ-5D Visual Analogue Scale score was
63.6 + 17.8 (mean + SD). The SF-36 Physical-Summary-Score
was 47.3  9.4 and the Mental Summary Score was 39.0  9.6.
CONCLUSION: Improvement of patients’ well-being is an
important objective of antipsychotic treatment. Baseline charac-
teristics of this schizophrenic cohort show that there is ample
space for improvement. Future analyses will focus on the rela-
tionship between adherence with therapy, symptomatology,
costs, and quality of life.
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OBJECTIVE: To determine the association between various
levels of comorbid anxiety and depression with health-related
quality of life and work-performance. METHODS: Patients from
an anxiety disorders program clinic completed the SF-36, Work
Limitations Questionnaire, Work Productivity and Activity
Impairment Questionnaire, Endicott Work Productivity Scale,
and Work Performance Scale. The Beck Anxiety Inventory (BAI)
and the Beck Depression Inventory (BDI) were used to determine
the severity of anxiety and depression, respectively. Patients were
categorized as lowBAI/lowBDI, highBAI/lowBDI, highBAI/
lowBDI, and highBAI/highBDI. The inﬂuence of severity of
anxiety/depression on the eight SF-36 scales, the SF-36 PCS and
MCS, and each work-performance instrument scale score was
determined using ANOVA with Scheffe post-hoc analyses. Mul-
tivariate linear regression assessed the combined association of
BAI and BDI on SF-36 and work-performance scales, controlling
for patient demographics. P values of <0.05 were statistically
signiﬁcant. RESULTS: Ninety-one patients provided complete
SF-36, BAI and BDI. Of these, 61 were employed. There were no
differences in demographics between groups. Post-hoc analy-
sis indicated that lowBAI/lowBDI patients had signiﬁcantly
higher MCS (41.2 + 10.9) compared to highBAI/lowBDI
(MCS = 29.9 + 8.3), lowBAI/highBDI (MCS = 23.7 + 15.8),
and highBAI/highBDI (MCS = 17.4 + 9.9). The difference
between highBAI/lowBDI and lowBAI/highBDI were not signiﬁ-
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cant. HighBAI/highBDI was signiﬁcantly different than the other
groups (p < 0.01). This pattern was similar for social function,
role emotion, mental health. Physical-related SF-36 domains
were generally not different between groups. The difference in
work-performance scale scores followed the same general pattern
of less impairment with lowBAI/lowBDI (for example, WPAI-
Percent Impairment While Working scale 0.22 + 0.3) and
highBAI/highBDI (WPAI Percent Impairment While Working
0.77 + 0.2), p < 0.01. Other work scales followed a similar
pattern. BDI routinely was more signiﬁcant in regression models
compared to BAI. CONCLUSION: Comorbid anxiety and
depression greatly impair patients. Clinicians and researchers
should measure the presence and severity of both mental illnesses
when assessing their inﬂuence on health-related quality of life
and work-performance.
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OBJECTIVE: While the clinical efﬁcacy of drugs for ADHD is
widely studied in clinical trials (usually randomised controlled
trials, RCTs), patient preferences with regard to their treatments
are not well understood and therefore considered to a less extent.
Aim of this study therefore was to explore the patients’ percep-
tions of an “ideal treatment” for ADHD. METHODS: Exami-
nation of the state of the art as reported in the literature was
followed by a qualitative study with four focus groups consisting
of 6–8 parents of ADHD-patients each. In a subsequent quanti-
tative study phase, data was collected in an online or paper-pencil
self-ﬁll-in questionnaire for parents of patients and patient (age
>14 years) themselves. It included sociodemographic data, treat-
ment history and actual treatment and patients’ preferences of
therapy characteristics using direct measurement (23 items on
a 5-point Likert-scale) as well as a discrete-choice-experiment
(DCE, 8 pairs with 6 characteristics). RESULTS: N = 213 ques-
tionnaires were ﬁlled; most of them by the parents of patients
(79% by the mothers, 9% by the fathers). Most of the patients
were male (83%) and most of them (83%) had actual medical
treatment of ADHD. Direct measurement showed “good emo-
tional quality of live”, “no addiction on medication”, “improve-
ment of concentration capability,” and “few side effects” in the
ﬁrst places. In the DCE, alternatives with “better social quality of
life (friendships etc. possible)”, “better emotional quality of life
(disease not all of the time mentally present)”, and “longer
duration of medication effect” were more likely to be chosen,
giving thus similar results. CONCLUSION: This unique study
demonstrates that it is possible to obtain valid and robust infor-
mation from patients on what constitutes relevant patient out-
comes. Such information should play a critical role in appraisal
of treatment alternatives by HTA bodies.
PMH62
ASSESSINGTHEVALIDITY OF DERIVING CLINICAL
DEMENTIA RATING (CDR) GLOBAL SCORES FROM
INDEPENDENTLY OBTAINED FUNCTIONAL RATING SCALE
(FRS) SCORES INVASCULAR DEMENTIA AND MIXED
VASCULAR DEMENTIA PATIENTS
Lanctôt KL1, Herrmann N1, Hsiung GYR2, Masoud ST1
1Sunnybrook Health Sciences Centre,Toronto, ON, Canada,
2University of British Columbia,Vancouver, BC, Canada
OBJECTIVE: The functional rating scale (FRS) and clinical
dementia rating (CDR) scale are two different tests used to assess
the severity and progression of dementia. Although the FRS
covers more domains and requires less time to administer than
the CDR, the CDR categorizes severity of dementia while the
FRS does not. The purpose of this research was to calculate the
agreement between the FRS and CDR scales and to determine if
they could be used interchangeably for diagnosis of disease sever-
ity in vascular dementia (VaD). METHODS: Inpatients and out-
patients diagnosed with VaD/mixed VaD were evaluated using
the FRS and CDR scales. The tests were administered indepen-
dently by two separate raters. Since the FRS contains all of the
domains that are rated in the CDR, CDR scores were extracted
from the corresponding FRS domains and used to derive global
scores of severity. FRS-derived global scores were then compared
to original CDR global scores by a weighted kappa analysis to
measure concordance. RESULTS: A total of 28 VaD/mixed VaD
patients were involved in the study. In the patient population,
60.7% were males and average age was 78.6  7.7 years.
Average MMSE score was 19.9  4.8 while mean Hachinski
score was 8.1  2.8. The modal value obtained for both the
FRS-derived CDR scores and original CDR scores was 2; in both
groups scores ranged from 0.5–3 with 43% of patients diagnosed
in category 2 (moderate dementia). The weighted kappa analysis
showed substantial concordance (kappa = 0.75) between FRS-
derived CDR and original CDR-global scores. CONCLUSION:
These results suggest that FRS scores can be used to derive global
scores that are in agreement with those produced by the validated
CDR method. This serves as a powerful tool since it allows for
easy comparison of the diagnostic distribution, natural history
and treatment outcomes of individuals with dementia.
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OBJECTIVE: Signal detection and, ultimately, regulatory
approval depend on high-quality, valid and reliable data. The
subjective rating scales utilized in CNS clinical trials may be
vulnerable to spurious ratings and intentional or unintentional
manipulation of ratings by investigators at screening or baseline
visits. The objective of this study was to evaluate the feasibility of
utilizing a patient reported outcome as a quality assurance
measure for evaluation of the quality of a clinician rated primary
efﬁcacy measure in a CNS clinical trial. METHODS: A propri-
etary ratings surveillance system was utilized in a multi-center,
double blind, randomized, placebo-controlled clinical trial in
which the Hamilton Anxiety Rating Scale (HARS) was the
primary efﬁcacy measure. The patient rated Beck Anxiety Inven-
tory (BAI) was added to the baseline visit for quality assurance
purposes. Based on published guidelines of the expected relation-
ship between HARS and BAI scores, a computer program ﬂagged
aberrant ratings and three ﬂags with the same rater triggered
a teaching intervention. The ratings surveillance system was
intended both to detect aberrant rating patterns and to deter
intentional inﬂation of ratings in order to qualify subjects.
RESULTS:The clinical trial is ongoing. 91 pairs of HARS and BAI
ratings have been examined from the randomization visit. 61/91
(67%) pairswere ﬂagged for discordance, inmost cases (79%) due
to disproportionately high HARS scores compared to the BAI. In
8 cases, the BAI was under 10 with the HARS 22 or greater. In 11
cases, there were at least 3 ﬂags for the same rater and the pattern
of discordance was considered to be of sufﬁcient clinical signiﬁ-
cance to warrant a teaching intervention. CONCLUSION: Use of
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